Danaher Corporation

Neutral score pending data. Fundamentals and price history will sharpen this as they ingest.

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services globally, with a primary focus on the United States, China, and other international markets. Operating through three key segments—Biotechnology, Life Sciences, and Diagnostics—the company provides bioprocessing technologies, consumables, and solutions that accelerate therapeutic development and manufacturing, including cell culture media, chromatography resins, filtration systems, and single-use hardware for full manufacturing suites. Its Life Sciences division supports advanced research tools, while Diagnostics offers essential testing and healthcare filtration solutions. Originally founded in 1969 and transformed through strategic acquisitions and divestitures, such as the 2023 spin-off of its environmental solutions into Veralto, Danaher now concentrates on scientific instruments and consumables in the diagnostics and research sector. Employing around 62,000 to 63,000 people under CEO Rainer Blair, Danaher plays a pivotal role in the healthcare and life sciences industries, driving innovation in biopharma production and medical diagnostics with a strong emphasis on recurring revenue streams.